Aura Biosciences: Aura Biosciences is a biotechnology company founded in 2007 and headquartered in the United States. The company is focused on developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications with high unmet need. Their mission is to deliver meaningful therapeutic benefit to cancer patients by establishing a new standard of care through innovative treatments.
At present, Aura Biosciences is directing its efforts towards the initial development of the VDC technology platform for addressing high unmet need tumors in ocular and urologic oncology. Their first VDC candidate, belzupacap sarotalocan (bel-sar), is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no approved drugs. Additionally, they are working on developing bel-sar for other ocular oncology indications, including choroidal metastasis, and have initiated a clinical program in non-muscle invasive bladder cancer (NMIBC).
The company recently received a $99.00M Post-IPO Equity investment on 06 November 2023.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $99.00M | - | 06 Nov 2023 | |
| Post-IPO Equity | $80.40M | - | 30 Nov 2022 | |
| Post-IPO Equity | Unknown | 1 |
|
03 Nov 2021 |
| Venture Round | $80.00M | 10 |
|
22 Mar 2021 |
| Venture Round | $10.00M | - | 09 Jul 2020 |
No recent news or press coverage available for Aura Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
